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Abstract
Background: The PI3K-Akt signal pathway plays a key role in tumorigenesis and the development of drug-resistance.
Cytotoxic chemotherapy resistance is linked to limited therapeutic options and poor prognosis.
Methodology/Principal Findings: Examination of FOXO3a and phosphorylated-Akt (P-Akt) expression in breast cancer
tissue microarrays showed nuclear FOXO3a was associated with lymph node positivity (p=0.052), poor prognosis
(p=0.014), and P-Akt expression in invasive ductal carcinoma. Using tamoxifen and doxorubicin-sensitive and -resistant
breast cancer cell lines as models, we found that doxorubicin- but not tamoxifen-resistance is associated with nuclear
accumulation of FOXO3a, consistent with the finding that sustained nuclear FOXO3a is associated with poor prognosis. We
also established that doxorubicin treatment induces proliferation arrest and FOXO3a nuclear relocation in sensitive breast
cancer cells. Induction of FOXO3a activity in doxorubicin-sensitive MCF-7 cells was sufficient to promote Akt
phosphorylation and arrest cell proliferation. Conversely, knockdown of endogenous FOXO3a expression reduced PI3K/
Akt activity. Using MDA-MB-231 cells, in which FOXO3a activity can be induced by 4-hydroxytamoxifen, we showed that
FOXO3a induction up-regulates PI3K-Akt activity and enhanced doxorubicin resistance. However FOXO3a induction has
little effect on cell proliferation, indicating that FOXO3a or its downstream activity is deregulated in the cytotoxic drug
resistant breast cancer cells. Thus, our results suggest that sustained FOXO3a activation can enhance hyperactivation of the
PI3K/Akt pathway.
Conclusions/Significance: Together these data suggest that lymph node metastasis and poor survival in invasive ductal
breast carcinoma are linked to an uncoupling of the Akt-FOXO3a signaling axis. In these breast cancers activated Akt fails to
inactivate and re-localize FOXO3a to the cytoplasm, and nuclear-targeted FOXO3a does not induce cell death or cell cycle
arrest. As such, sustained nuclear FOXO3a expression in breast cancer may culminate in cancer progression and the
development of an aggressive phenotype similar to that observed in cytotoxic chemotherapy resistant breast cancer cell
models.
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Introduction
Breast cancer is the most common malignancy in women and
represents one of the major causes of death worldwide. Endocrine
agents have become the primary adjuvant treatment for breast
cancer [1,2]. Tamoxifen, a selective estrogen receptor modulator
(SERM), is widely used for treating estrogen receptor a (ERa)
positive breast cancer patients. Although most ERa positive breast
cancer patients initially respond to tamoxifen therapy, approxi-
mately half of the patients will eventually develop resistance and
relapse, following long-term treatment [1,3,4,5]. The effects of
Tamoxifen in breast tissues result from its ability to bind to the
ligand-binding domain of the ERa, thereby antagonizing the
proliferative potential of estrogen [1,2]. Other similar strategies,
including estrogen withdrawal and pure estrogen antagonism,
have also been employed to block the mitogenic effects of estrogen
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adopt as yet unclear mechanisms to develop insensitivity or
resistance [6,7]. Although the predictive markers for endocrine
therapy response, namely expression of ERa and progesterone
receptor are popularly used for determining clinical management
[8,9], survival signaling pathways regulated by PI3K, Akt (also
called PKB) and PTEN are also found to be crucial in drug
resistance [4,10,11,12,13], indicating that multiple biomarkers are
required to fully predict the development of drug resistance.
For those breast cancer patients who relapse after endocrine
treatment or those with tumours that do not express hormone
receptors, chemotherapeutic agents, including taxenes (eg. Pacli-
taxel and Docetaxel) and anthracyclins (eg. Epirubicin and
Doxorubicin), represent important backup treatment options
[1,2]. These systemic chemotherapy backup treatments are also
essential for patients with metastatic or advanced stage breast
cancer. However, for those breast cancer patients who are
unresponsive or have subsequently become resistant to taxane
and anthracycline-based chemotherapies, their treatment options
are limited and their outlook is poor. Although taxane and
anthracycline-based chemotherapeutic regimens can stop cancer
cells from multiplying, their non-specific actions damage normal
healthy cells, curtailing further treatment. It is therefore important
to develop good predictors for chemotherapy response, so that
these agents are only used for treating patients responsive to the
treatment; whereas non-responsive patients can be switched to
alternative treatments at an early stage.
Previous studies have shown that increased Akt activity can
promote breast cancer cell survival and therapeutic resistance
[6,7,10,11]. Furthermore, the PI3K-Akt signaling pathway has
also been demonstrated to play a crucial role in the development
of tamoxifen resistance [10,11,12]. FOXO transcription factors
(FOXO3a, FOXO1 and FOXO4) are downstream targets of the
PI3K-Akt pathway, which play a vital role in a variety of cellular
processes, such as cellular differentiation, tumour suppression,
metabolism, cell cycle arrest, cell death and protection from stress
[14]. Akt phosphorylates three sites on FOXO proteins leading to
their nuclear exclusion and inactivation, which is known to
associate with tumorigenesis and cancer progression [15].
Most studies on FOXO3a in breast cancer have been conducted
on breast cancer cell lines or animal models. For the few
expression studies of FOXO3a in breast cancer patient samples,
the results have been conflicting. Hu et al (2004) [16] have found
cytoplasmic expression of FOXO3a correlated with phosphory-
lated Akt (P-Akt) and associated with poor survival in breast
cancer. Yet, another study found that nuclear rather than
cytoplasmic FOXO3a was significantly associated with lymph
node metastasis [17]. To explore the potential role of the Akt-
FOXO3a axis in breast cancer prognosis, we studied the
expression of FOXO3a and P-Akt in a tissue microarray of 130
breast cancer cases. Contrary to previous findings of Hu et al
(2004) [16], we found predominant nuclear accumulation of
FOXO3a was associated with poor prognosis and active P-Akt
expression, suggesting an uncoupling of the Akt-FOXO3a axis
during breast cancer progression and development of drug
resistance. To validate these findings, we studied FOXO3a
nuclear expression and its consequence in a panel of chemother-
apy sensitive and resistant breast cancer cell lines.
Materials and Methods
Tissue Microarray
One hundred and thirty-three cases of breast cancer diagnosed
between the years 1992 to 2001 with clinical follow up data were
retrieved from the records of the Department of Pathology, Queen
Mary Hospital of Hong Kong. The patients’ ages at diagnosis
ranged from 30 to 90 years old, with a mean of 53 years.
Histological sections of all cases were reviewed by the pathologist,
the representative paraffin tumour blocks chosen as donor block
for each case and the selected areas marked for construction of
tissue microarray blocks. Of all cases, 38 had non-tumour tissues
available for comparison with their tumour counterparts in protein
expression studies. A total of 120 could be assessed and scored for
FOXO3a and P-Akt expression. The expression pattern and
subcellular localization were correlated with histological type,
histological grade, clinical stage, estrogen and progestrogen
receptor status, HER2 oncoprotein overexpression, lymph node
metastasis and survival time.
Immnohistochemistry
Tissue sections were deparaffinized and rehydrated by incuba-
tion with xylene and decreasing concentrations of ethanol. Citrate
buffer (0.01 M, pH 6.0) was used for antigen retrieval. The slides
were immersed into 3% H2O2/methanol for 10 min at room
temperature to quench endogenous peroxidase. After rinsing in
0.05% Tween in PBS (PBST) twice, a previously described
primary polyclonal FOXO3a specific antibody [18,19] diluted at
1:1400 and P-Akt (Thr308) polyclonal (Cell Signaling, New
England Biolabs, Hitchin, UK) diluted at 1:100 were separately
added to each section and incubated at 4uC overnight. The slides
were then washed in PBST and 4–5 drops of DAKO Polymer
were applied on each section and incubated at room temperature
for 30 min. After washing, Chromogen DAB/substrate reagent
was added onto the slides and the slides incubated for a further
3 min. Finally, the slides were dehydrated with increasing
concentrations of ethanol followed by clearing in xylene and then
mounted.
The staining of FOXO3a and P-Akt were assessed by light
microscope visualized at high power (X170). The staining intensity
and percentage of staining in the cytoplasm and the nucleus were
scored in a semi-quantitative fashion. The intensity of staining was
scored as follows: 1= weak, 2= moderate, 3= strong. The
percentage of cells positively stained was scored as follows:
1#25%, 2#50%, 3#75%, 4.75%. For each case, a final score
from the nucleus and the cytoplasm was obtained by multiplying
the score of intensity with the score of percentage, 12 being the
maximum final score. To avoid subjectivity in evaluation, scoring
was done by two independent individuals.
Statistical Analysis
Statistical analysis was performed using the SPSS programme
version 16. Correlation of FOXO3a or P-Akt expression to clinical
and histological data was assessed by Chi-square test or Fisher’s-
exact test where applicable. Survival analysis was assessed by
Kaplan Meier analysis using log-rank test. P-values of less than or
equal to 0.05 were considered statistically significant.
Cell Lines and Cell Culture
The human breast cancer cell lines MCF-7, BT474 and MDA-
MB-231 originated from the American Type Culture Collection
and were acquired from the Cell Culture Service, Cancer
Research UK (London, UK), where they were tested and
authenticated. All cells were cultured in DMEM, while MDA-
MB-231-FOXO3a(A3):ER was cultured in DMEM-phenol red
free, all supplemented with 10% foetal bovine serum, 2 mmol/L
glutamine and 100 units/mL antibiotics (penicillin and strepto-
mycin) (Sigma, Poole, UK), in a humidified incubator at 37uC
with 5% CO2. The MCF-7DOX
R cell line is a doxorubicin
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estrogen-independent and tamoxifen-resistant cell lines, LCC2
and LCC9 were derived from MCF-7/LCC1 by stepwise in vitro
selection of prolonged tamoxifen (LCC2) and fulvestrant (LCC9)
treatment as described [20], while R27 is also a tamoxifen resistant
cell line derived from parental MCF-7 (LCC1). Following in vitro
selection, they were maintained in modified IMEM-phenol red
free with 5% charcoal-stripped FBS. All the tamoxifen resistant
cell lines were kindly provided by Dr Robert Clarke (Georgetown
University Medical School, Washington. D.C.).
Sulforhodamine B (SRB) assay
Approximately 3000 cells were seeded in each well of the 96
well plates. After culture, 100 ml of trichloroacetic acid was added
to each well and incubated for 1 h at 4uC. The plates were then
washed with deionised water for three times, before incubation at
RT for 1 h with 0.4% SRB in 1% acetic acid. The plates were
then washed with deionised water and air-dried. 10 mM Tris base
was then added to the wells to solubilise the bound SRB dye, and
the plates were then read at 492 nm using the Anthos 2001 plate
read (Jencons Scientific Ltd, Leighton Buzzard, UK).
Cell Cycle Analysis
Cell cycle analysis was done by propidium iodide (PI) staining
Cells were seeded and serum starved for 24 h. With or without
tamoxifen treated cells were trypsinized and then fixed in cold
70% ethanol after PBS wash. All the fixed cells were incubated in
PBS with 5 mg/mL propidium iodide, 0.1 mg/mL RNase A and
0.5% Triton X-100 for 45 min at 37uC before analysis using a
Becton Dickinson FACS analyzer (Oxford, UK). The cell cycle
data were further analyzed by WinMDI 2.9.
Drug Treatment Assay
For drug treatment, all cell lines were cultured in DMEM with
10% FBS, 2 mmol/L glutamine and 100 units/mL antibiotics
(penicillin/streptomycin). Exponentially growing cells were incu-
bated with 0.1 mM tamoxifen or 1 mM doxorubicin for the
indicated time course, unless specified otherwise.
Western Blot Analysis and Antibodies
Cells were lysed and SDS-PAGE gel electrophoresis was
performed as previously described [21]. Harvested cells were lysed
in protein lysis buffer (1% NP-40, 150 mM NaCl, 50 mM, 50 mM
Tris-HCl (pH 7.4), 0.5% Sodium deoxycholate, 0.1% SDS, 2 mM
EDTA, 1 mM PMSF and protease inhibitors (‘‘Complete’’ protease
inhibitor mixture, as instructed by the manufacturer Roche Applied
Science, Lewes, UK) and the protein concentration was determined
by Bio-Rad Dc protein assay (Bio-Rad, Hemel Hempstead, UK).
Twentymicrogramsofeach proteinsamplewere separatedbySDS-
PAGE, electrophoretically transferred onto Protran nitrocellulose
membranes (Schliecher and Schuell, Dassel, Germany). After
blocking in 5% BSA/TBST for 1 h at room temperature,
membranes were probed with the respective primary antibodies
at 4uC overnight and then detected using horseradish peroxidase
linked anti-mouse, anti-goat or anti-rabbit conjugates as appropri-
ate (DAKO, Ely, UK.), and visualized using the ECL detection
system (Amersham Biosciences, Amersham, UK). Primary anti-
bodies used were P-FOXO3a (Thr32), FOXO3a, P-Akt (Ser473)
and Akt (all from Cell Signaling, UK), Lamin B (C-20) and b-
tubulin (H-235) (Santa Cruz Biotechnology,Wiltshire, UK). The
expression of FOXO isoforms has previously been studied in these
breast cancer cell lines, and FOXO3a has been shown to be the
predominant species [22].
Nuclear and cytoplasmic lysate extraction
The fractionation was done by using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermo Fisher, Horsham, UK)
following the manufacturer’s protocol.
Transfection of FOXO3a expression vector
The FOXO3a expression vector pECE-TM-FOXO3a
(FOXO3a (A3)), triple mutant FOXO3a in which all three P-
Akt phosphorylation sites were mutated to alanine), encoding
constitutively active FOXO3a, was obtained from Addgene
(Cambridge, MA, USA). The FOXO3a(A3) insert was then
cloned into vector pcDNA3.1(+) (Invitrogen, Paisley UK) for
further study. For overexpression assay, MCF-7 cells were seeded
into 24-well 24 h before transfection. Two microliter lipofecta-
mine 2000 (Invitrogen, UK) and 0.8 mg FOXO3a (A3), plasmid
were used for each well.
Gene Silencing with Small hairpin RNAs (shRNAs)
For gene silencing, cells were seeded in 24-well plates and
transfected with 0.8 mg FOXO3a shRNA (SABiosciences, USA)
using lipofectamine 2000 system (Invitrogen). After 24 hours, total
RNA was extracted to check knockdown efficiency by real-time
quantitative PCR while total protein was used in Western blot
assay.
Real-time Quantitative PCR (RTQ-PCR)
TRizol reagent (Invitrogen) was used for total RNA extraction.
One microgram of total RNA was reverse-transcribed into cDNA
using High Capacity RNA-to-cDNA Master Mix (Applied
Biosystems, Brackley, UK). The cDNA was then used as the
template in the real-time quantitative PCR analysis while gene
TBP was used as the endogenous control. The gene-specific
primer pairs were showed in Table 1. Detection of FOXO3a and
PIK3CA transcription level was performed with Power SYBR
Green kit (Applied Biosystems, UK) with ABI 7800 system
(Applied Biosystems, UK).
Immunofluorescent Staining
Cells were subjected to anti-FOXO3a staining. Briefly, cells
were fixed with 4% paraformaldehyde (Sigma, UK), permeabi-
lized with 0.1%Triton X-100 in 10% FCS for 10 min. Samples
were then blocked with 5% goat serum for 30 min and then
incubated overnight with the primary rabbit anti-FOXO3a (Cell
Signaling, UK). Following washes with PBS, secondary goat anti-
rabbit IgG-FITC (1:500, Invitrogen) was added to the samples for
an hour. Cells were counterstained with 49,6 9-diamidino-2-
phenylindole (DAPI; Sigma UK) before mounting. Images were
captured and quantified using the Zeiss Axiovert 100 confocal
laser scanning microscope and software Zeiss LSM 500 (Zeiss Ltd).
Table 1. Gene-specific primer pairs.
Primer Sequence
FOXO3a-forward 59-TCTACGAGTGGATGGTGCGTT-39
FOXO3a-reverse 59-CGACTATGCAGTGACAGGTTGTG-39
PIK3CA-forward 59-AAATGAAAGCTCACTCTGGATTCC-39
PIK3CA-reverse 59-TGTGCAATTCCTATGCAATC-39
TBP-forward 59-ACGAACCACGGCACTGAT-39
TBP-reverse 59-AACCCAACTTCTGTACAACTCTAGCA-39
doi:10.1371/journal.pone.0012293.t001
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Nuclear FOXO3a expression in breast cancer tissue is
significantly associated with lymph node metastasis and
poor survival in invasive ductal carcinoma
To explore the potential role of the Akt-FOXO3a signaling axis
as prognostic markers in breast cancer, the expression patterns of
FOXO3a and P-Akt were studied using immunohistochemical
staining on a panel of breast cancer samples (Table 2). The
staining of FOXO3a revealed both nuclear and cytoplasmic
localization in tumours (Table 3). Representative expression
patterns in both tumour and non-tumour samples were shown in
Figure 1A. Stronger cytoplasmic FOXO3a staining was observed
to be common in tumour samples (P,0.0001, Chi-Square test).
FOXO3a cytoplasmic staining (p,0.0001, Chi-Square test) was
also significantly associated with P-Akt staining, which is
supportive that the activated P-Akt can negatively regulate
FOXO3a and relocate it from the nuclear to cytoplasm in most
breast cancer samples.
The majority of tumour samples are invasive ductal carcinoma.
Therefore, we re-analyzed the above parameters for cases of
invasive ductal carcinomas only, and found that the nuclear
staining of FOXO3a was correlated with lymph node positivity
(p=0.052, Chi-Square test). Furthermore, FOXO3a nuclear
staining was also significantly associated with shorter survival time
(p=0.014, log-rank test) (Fig. 2). Interestingly, using the
comparison scoring system N. =
Co rC .N as previously described
[16], the N. =
C FOXO3a staining of all cases irrespective of
histological types was positively associated with the P-Akt staining
(p=0.039, Chi-square test), suggesting uncoupling of the Akt-
FOXO3a signaling axis is associated with lymph node metastasis
and poor survival in invasive ductal carcinoma. Representative
stainings are showed in Figure 1B. Together these findings indicate
that the function of FOXO3a and its control by Akt have been
deregulated in breast cancer associated with lymph node
metastasis and poor survival, indicative of cancer progression
and treatment failure, respectively.
Tamoxifen-resistant breast cancer cell lines are sensitive
to doxorubicin treatment
In order to confirm and explore further the immunohistochem-
ical findings from patientsamples, wesoughttovalidate ourfindings
in breast cancer tissue culture cell models. To this end, we first
studied the drug resistance of a panel of chemotherapy (i.e.
tamoxifen and doxorubicin) sensitive and resistant breast cancer cell
lines. Proliferative assay results indicated that while the parental
MCF-7 cell line is sensitive to tamoxifen, other MCF-7 derivative
clones, LCC2, LCC9, R27as well as the BT474 cells are resistant to
tamoxifen treatment from concentrations 2.5 to 5 mM (Fig. 3). We
also generated a cytotoxic chemotherapy resistant MCF-7 cell line
through continuous exposure up to 10 mM doxorubicin, and
proliferative analysis confirmed that the proliferation of this MCF-
7Dox
R cell pool is not significantly affected by doxorubicin
treatment (Fig. 4A). In contrast, the proliferation of the parental
MCF-7 cells was severely inhibited when incubated with . =
1 mMo f
doxorubicin.Similarly,themultidrug resistantbreastcarcinomacell
line MDA-MB-231 was also resistant to 1 mM of doxorubicin, a
dose that effectively inhibits the parental MCF-7 cell proliferation
(Fig. 4B). Notably, the tamoxifen resistant BT474 cells as well as the
MCF-7 derived lines, including LCC2, LCC9 and R27, were all
found to be sensitive to doxorubicin treatment at 10 mM (Fig. 4C).
The MCF-7 Dox
R and MDA-MB-231 may represent breast
cancers that have progressed and become drug resistant. This
finding corroborates with the clinical evidence that breast cancers
which failed endocrine treatments are often intrinsically sensitive to
cytotoxic chemotherapy.
Predominant nuclear FOXO3a localization in
doxorubicin- but not tamoxifen-resistant breast cancer
cell lines
To explore the potential role of FOXO3a and its upstream
regulator Akt in the development of drug resistance, we first
examined the basal expression levels of both the total and
phosphorylated forms of FOXO3a and Akt in the drug sensitive as
well as resistant breast cancer cell lines. Western blot analysis
showed that the tamoxifen sensitive MCF-7 (LCC1) and resistant
cell lines LCC2, LCC9 and R27 expressed comparable levels of P-
Akt (Ser-473), FOXO3a and P-FOXO3a (Thr-32) (Fig. 5A),
suggesting elevated P13K-Akt activity in both the endocrine
sensitive and resistant cells. In contrast, BT474 cells expressed
higher levels of P-Akt (Ser-473), and P-FOXO3a (Thr-32) but also
more FOXO3a. Interestingly, P-Akt (Ser-473) and total Akt were
expressed at similar levels in the doxorubicin sensitive MCF-7 and
resistant MCF-7Dox
R and MDA-MB-231 cells (Fig. 5B). By
comparison, the expression levels of P-FOXO3a (Thr-32) were
Table 2. Histological types of tumour samples used in tissue
microarray.
Pure ductal cell carcinoma in situ (pure DCIS) 10
Invasive ductal carcinoma 94
Invasive lobular carcinoma 2
Pure tubular or cribriform 1
Tubular mixed 5
Pure mucinous carcinoma 2
Medullary or atypical medullary 1
Others* 5
Total 120
*Others: 3 cases of mixed lobular and ductal carcinoma, 1 case of intraduct
papillary carcinoma and 1 case of carcinosarcoma.
doi:10.1371/journal.pone.0012293.t002
Table 3. FOXO3a immunoreactivity in all cases.
Tumour cases
Nuclear
staining No. of cases
Cytoplasmic
staining No. of cases
negative 85 negative 4
N score #6 25 C score #62 4
N score .6 10 C score .69 2
Total 120 Total 120
Non-tumour cases
Nuclear
staining No. of cases
Cytoplasmic
staining No. of cases
negative 0 negative 17
N score #6 27 C score #61 4
N score .6 11 C score .67
Total 38 Total 38
doi:10.1371/journal.pone.0012293.t003
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R while the expression levels of total
FOXO3a were high in both the MCF-7Dox
R and MDA-MB-231
cells. These results indicate that substantial amounts of FOXO3a
were not phosphorylated and the Akt-FOXO3a axis is uncoupled
in the doxorubicin resistant cells.
We next investigated the subcellular distribution of FOXO3a
in the cytoplasmic and nuclear extracts from these drug sensitive
and resistant breast cancer cell lines (Fig. 6A). Lamin B and
tubulin were also probed as controls for effective nuclear and
cytoplasmic fractionation respectively. While FOXO3a was
detected at considerably higher levels in the cytosolic fractions
compared with the nuclear fractions in all doxorubicin sensitive
breast cancer, FOXO3a expression was found at appreciably
higher levels in the nuclear fractions in the doxorubicin resistant
breast cancer cells MCF-7Dox
R and MDA-MB-231. These
results suggest that FOXO3a expression was primarily nuclear
in doxorubicin-resistant cells, but was predominantly cytoplas-
mic in doxorubicin-sensitive cells. This result was also observed
in tamoxifen-resistant BT474, LCC2 and LCC9 cell lines
(Fig. 6A).
To confirm the subcellular fractionation results, immunofluo-
rescent staining was then used to directly visualize the subcellular
distribution of FOXO3a in the doxorubicin sensitive MCF-7 and
BT474 and the drug resistant MCF-7Dox
R and MDA-MB-231
cells (Fig. 6B). The results showed that FOXO3a staining was
primarily located in the cytoplasm of the doxorubucin sensitive cell
lines, MCF-7 and BT474. In contrast, FOXO3a was expressed
predominantly in the nucleus in doxorubucin resistant MCF-
7Dox
R and MDA-MB-231 cells, further suggesting that the
development of cytotoxic drug resistance may be associated with
nuclear FOXO3a localization. These findings are consistent with
the immunohistochemical staining results that increased Akt
Figure 1. Representative expression patterns of FOXO3a and P-Akt in tissue microarray. Tumour tissue samples obtained from breast
cancer patients that had been formalin-fixed and paraffin-embedded were immunohistochemically stained with FOXO3a and P-Akt (Thr308)
antibodies using the streptavidin-biotin-peroxidase technique. A) Representative FOXO3a staining patterns in both tumour and non-tumour cases
(magnification6170). B) Two representative tumour cases showing corresponding FOXO3a and P-Akt staining patterns (magnification6170). Case 1
shows high cytoplasmic pAkt staining and strong cytoplasmic and nucleus FOXO3a staining. Case 2 shows weak pAkt and FOXO3a staining.
doi:10.1371/journal.pone.0012293.g001
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12293Figure 2. Survival Analysis with nuclear FOXO3a staining in invasive ductal carcinoma cases. Of the 120 cancer samples assessed, there
were 94 cases of invasive ductal carcinoma. The correlation between nuclear FOXO3a expression and survival was studied using Kaplan Meier analysis
(P=0.014) and was considered significant at p,0.05.
doi:10.1371/journal.pone.0012293.g002
Figure 3. Effects of tamoxifen on cell proliferation of a panel of breast carcinoma cell lines. MCF-7(LCC1), LCC2, LCC9, R27 and BT474 cells
were treated with 0 to 10 mM of tamoxifen for 6 days. Cell proliferation was determined by SRB assay. Points, mean of three independent
experiments; bars, SD.
doi:10.1371/journal.pone.0012293.g003
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expression is associated with poor prognosis in breast cancer.
Doxorubicin induces FOXO3a nuclear relocation in drug
sensitive cells
To explore the potential role of FOXO3a in drug response and
resistance, FOXO3a expression was examined in the cytoplasmic
and nuclear fractions of the sensitive MCF-7 and the resistant
MCF-7Dox
R and MDA-MB-231 cells in response to doxorubicin
treatment. The Western blot results showed that FOXO3a
expression increased in the nucleus, with a reciprocal decrease
in levels in the cytoplasm in the sensitive cells, 12 and 24 h
following doxorubicin treatment (Fig. 7A). Contrarily, FOXO3a
expression levels remained unchanged in both the cytoplasmic and
Figure 4. Effects of doxorubicin on cell proliferation of a panel of breast carcinoma cell lines. A) MCF-7 and the derived MCF-7 Dox
R cells
were treated with 0 to 10 mM of doxorubicin for 0, 24, and 48 h. B) MCF-7, MCF-7 Dox
R, MDA-MB-231, BT474, and LCC9 cells were treated with 1 mM
of doxorubicin for 0, 24, and 48 h. C) MCF-7(LCC1), LCC2, LCC9, R27 and BT474 cells were treated with 1 mM of doxorubicin for 0, 24, and 48 h. Cell
proliferation was determined by SRB assay. Points, mean of three independent experiments; bars, SD.
doi:10.1371/journal.pone.0012293.g004
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cells in response to doxorubicin. To confirm the subcellular
fractionation results, immunofluorescent staining was again used
to gauge the subcellular distribution of FOXO3a in the
doxorubicin sensitive MCF-7 and the drug resistant MCF-7DoxR
and MDA-MB-231 cells in response to doxorubicin treatment
(Fig. 7B). The results showed that FOXO3a relocated to the
nucleus in the MCF-7 cells following 16 h of doxorubicin
treatment, while the subcellular expression patterns of FOXO3a
remained largely unchanged in the doxorubicin resistant cells.
Together these results suggested that doxorubicin causes nuclear
relocation of FOXO3a in the drug sensitive breast cancer cells,
and confirmed our previous data that FOXO3a expression is
predominantly nuclear in the resistant cells.
Ectopic FOXO3a expression results in proliferation arrest
and enhances Akt phosphorylation in cytotoxic drug
sensitive cells
To examine the role of FOXO3a in drug response, we examined
the effects of overexpression of FOXO3a in the sensitive cell line
MCF-7.The drug sensitiveMCF-7cellsweretransiently transfected
with an expression vector encoding a constitutively active
FOXO3a(A3), in which all three Akt-phosphorylation sites were
mutated to alanine. The results revealed that ectopic FOXO3a(A3)
expression not only enhances Akt phosphorylation without altering
total Akt expression levels(Fig.8A),butalsoattenuatedproliferation
(Fig.8C). This is consistent with a previous report using chronic
myeloid leukaemia (CML) cell lines showing that FOXO3a
overexpression can result in an increase in PI3K-Akt activity [23].
The gene PIK3CA, which encodes the PI3K catalytic subunit, has
previously been demonstrated to be a direct downstream target of
transcription factor FOXO3a in CML [23,24]. Our experiments
showed that ectopic expression of FOXO3a(A3) could enhance the
expression of PIK3CA transcriptionally (Fig. 8B). Furthermore,
ectopic expression of FOXO3a(A3) could also block cell prolifer-
ation in the MCF-7, suggesting that doxorubicin inhibition of cell
proliferation is at least in part through FOXO3a in the cytotoxic
chemotherapeutic resistant breast cancer cells.
To confirm the observation that FOXO3a regulates Akt
activity, specific shRNAs were used to knockdown the endogenous
FOXO3a expression in the doxorubicin sensitive BT474 cell line
which exhibits high PI3K-Akt activity. The knockdown effect of
FOXO3a shRNAs in BT474 was confirmed by Western blot
analysis (Fig. 9A) and at mRNA levels using Real-time quantitative
(RTq)-PCR (Fig. 9B). FOXO3a knockdown induced a corre-
sponding reduction in the levels of PIK3CA transcripts (Fig. 9B)
and P-Akt (Ser-473) (Fig. 9A).
FOXO3a activation promotes Akt phosphorylation but
not proliferation arrest in drug resistant breast cancer
cells
To study the effects of FOXO3a activation in drug resistant
breast cancer cells, we used a MDA-MB-231 cell line harbouring
an expression vector that encodes the hormone binding domain of
estrogen receptor a (ERa) fused to the constitutively active
FOXO3a(A3). In these MDA-MB-231-FOXO3a(A3):ER cells,
FOXO3a activity can be conditionally induced upon the addition
of Tamoxifen (4-OHT). Western blot analysis showed that
treatment of MDA-MB-231-ER:FOXO3a(A3) cells with 4-OHT
induced the relocation of FOXO3a from the cytoplasm to the
nucleus fractions (Fig. 10A). The result also showed that the
relocation of FOXO3a(A3):ER to the nucleus upon 4-OHT
treatment enhanced Akt phosphorylation without significantly
altering total Akt expression levels. This increase in Akt
phosphorylation, and thus PI3K-Akt activity, was specifically
mediated by FOXO3a induction, as no such response was
observed in the control MDA-MB-231 cells expressing ER alone.
Consistent with this, RT-qPCR analysis also showed that
treatment with 4-OHT also induced the expression of the
FOXO3a target genes, PIK3CA and IGFR1 (Fig. 10B). However,
only p110a the gene product of PIK3CA, could be detected at
protein levels in these cells upon FOXO3a induction (Fig. 10A).
The nuclear relocation of FOXO3a(A3):ER in response to 4-OHT
induction in the MDA-MB-231-FOXO3a(A3):ER cells was
Figure 5. Expression of total and phosphorylated Akt and
FOXO3a in a panel of tamoxifen and/or doxorubicin sensitive
and resistant breast carcinoma cell lines. The tamoxifen sensitive
MCF-7(LCC1), and resistant LCC2, LCC9, R27 and BT474 cells as well as
the doxorubicin sensitive MCF-7 and resistant MCF-7-Dox
R and MDA-
MB-231 cells were cultured in normal growth medium and used for
Western blot analysis for P-Akt (Ser473), total Akt, P-FOXO3a (Thr32),
total FOXO3a and b-tubulin.
doi:10.1371/journal.pone.0012293.g005
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PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12293Figure 6. Nuclear location of FOXO3a in a panel of tamoxifen and/or doxorubicin sensitive and resistant breast carcinoma cell lines.
The tamoxifen sensitive MCF-7(LCC1), and resistant LCC2, LCC9, R27 and BT474 cells as well as the doxorubicin sensitive MCF-7 and resistant MCF-7-
DoxR and MDA-MB-231 cells were cultured in normal growth medium and used for studies of the subcellular localization of FOXO3a. A) Cytoplasmic
and nuclear protein lysates were prepared and protein expression levels were analyzed by Western blotting using antibodies against specific
antibodies against FOXO3a, lamin B1 and and b-tubulin, B) The cells were cultured on sterile coverslips, before being fixed in 4% formaldehyde.
FOXO3a expression was visualized with a specific rabbit polyclonal antibody against FOXO3a followed by the addition of ALEX488 (green) labeled
anti-rabbit antisera. DAPI (blue) were also applied to visualize the nuclei.
doi:10.1371/journal.pone.0012293.g006
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(ER) (Fig. 11A). Notably, the induction of FOXO3a activity in the
drug resistant MDA-MB-231 cells did not cause significant
changes in the rate of cell proliferation (Fig. 11B), indicating that
the anti-proliferative function of FOXO3a is deregulated in the
cytotoxic drug resistant cells. This might help to explain why the
breast cancers of poor prognosis can tolerate nuclear FOXO3a.
FOXO3a function is deregulated in the drug resistant
breast cancer cells
To confirm further that the anti-proliferative function of
FOXO3a is deregulated in the cytotoxic drug resistant cells, the
doxorubicin resistant MCF-7Dox
R cells were transfected with
either the empty expression vector or one that encodes for the
constitutively active FOXO3a(A3) (Fig. 12A) and cultured with
Figure 7. Doxorubicin treatment causes a nuclear relocation of FOXO3a expression. The doxorubicin sensitive MCF-7 and resistant MCF-7-
Dox
R and MDA-MB-231 cells were treated with 1 mM doxorubicin. A) Cytoplasmic and nuclear protein lysates were prepared at the times indicated
after doxorubicin treatment and protein expression levels were analyzed by Western blotting using antibodies against specific antibodies against
FOXO3a, lamin B1 and and b-tubulin, B) The cells were cultured on sterile coverslips and treated for 16 h with or without 1 mM doxorubicin, before
being fixed in 4% formaldehyde. FOXO3a expression was visualized with a specific rabbit polyclonal antibody against FOXO3a followed by the
addition of ALEX488 (green) labeled anti-rabbit antisera. DAPI (blue) were also applied to visualize the nuclei.
doi:10.1371/journal.pone.0012293.g007
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PLoS ONE | www.plosone.org 10 August 2010 | Volume 5 | Issue 8 | e12293Figure 8. Overexpressed active FOXO3a results in cell proliferation arrest and Akt phosphorylation in drug sensitive breast cancer
cell line MCF-7. MCF-7 cells were transiently transfected with the constitutively active FOXO3a(A3) or control vector, and the transfected cells
analysed by A) Western blot analysis for FOXO3a, P-Akt (Ser473), Akt and b-actin. B) The transfected cells were also examined by qRT-PCR analysis for
FOXO3a and PIK3CA mRNA expression. TBP mRNA was used as an internal control. C) SRB assays were performed on these transfected cells,
indicating that the ectopic expression of FOXO3a(A3) decreases the cell proliferation rate.
doi:10.1371/journal.pone.0012293.g008
Figure 9. Knockdown of FOXO3a expression decreases Akt phosphorylation and PIK3CA mRNA expression. BT474 cells were
transiently transfected with FOXO3a or control shRNA, and 24 h after transfection cells were analysed by A) Western blot using specific antibodies P-
FOXO3a (Thr32), FOXO3a, P-Akt (Ser473), Akt and Actin as indicated and by B) qRT-PCR.
doi:10.1371/journal.pone.0012293.g009
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ed that overexpression of the active FOXO3a(A3) did not result in
any significant decreases in proliferative rate (Fig. 12B), suggesting
that the anti-proliferative function of FOXO3a is deregulated in
the cytotoxic drug resistant cells. This result also argues against the
possibility that FOXO3a mutation is the predominant cause of
drug insensitivity in the drug resistant cells. To examine further the
effects of FOXO3a activation on drug resistance in breast cancer
Figure 10. FOXO3a induces Akt phosphorylation, PIK3CA and IGFR1 gene expression in the drug resistant MDA-MB-231 breast
carcinoma cells. MDA-MB-231-FOXO3a(A3):ER and MDA-MB-231 cells were treated with 200 nM 4-OHT for the indicated times. A) Total,
cytoplasmic and nuclear extracts were prepared at the times indicated, separated on polyacrylamide gels, and subjected to immunoblotting with
specific antibodies. The expression levels of FOXO3a, P-FOXO3a (Thr-32), p110a (PIK3CA), P-Akt (Ser473), Akt, and lamin B1 were analyzed by Western
blotting. B) Total RNA was extracted from these cells and analyzed for PIK3CA, and IGFR1, mRNA expression using qRT-PCR as described in the text
and normalized to the level of L19 RNA. All data shown represent the averages of data from three experiments, and the error bars show the standard
deviations.
doi:10.1371/journal.pone.0012293.g010
Nuclear FOXO3a Localization
PLoS ONE | www.plosone.org 12 August 2010 | Volume 5 | Issue 8 | e12293cells, the MDA-MB-231-FOXO3a(A3):ER cells were treated with
either the vehicle (ethanol) or 4-OHT and subjected to
doxorubicin treatment. Western blot analysis of cytosolic and
nuclear protein fractions showed increased nuclear and decreased
cytoplasmic FOXO3a levels after 4 h of tamoxifen treatment,
implying increased FOXO3a transcriptional activity (Fig. 13A).
FOXO3a activation also resulted in an increase in Akt activity, as
revealed by the increased in P-FOXO3a (Thr-32) expression.
Notably, at 24 and 48 h after FOXO3a(A3):ER induction, there
was an accumulation of endogenous FOXO3a, which can
probably help to explain for the late induction in Akt activity as
well as the expression of FOXO3a targets. Proliferative assays
demonstrated that high levels of doxorubicin significantly
decreased the proliferation rates of the vehicle-treated MDA-
MB-231-FOXO3a(A3):ER cells, indicating that these cells are
sensitive to high levels of doxorubicin (Fig. 13B). Interestingly, the
results also showed that activation of FOXO3a(A3):ER by 4-OHT
can confer resistance to the anti-proliferative effects of high levels
of doxorubicin in the MDA-MB-231-FOXO3a(A3):ER, further
confirming that FOXO3a function is deregulated in the drug
resistant breast cancer cells.
Discussion
Tamoxifen and cytotoxic chemotherapy are commonly used for
the treatment of breast cancer patients worldwide. In breast
cancer, numerous endocrine therapeutic strategies have been
developed to target the estrogen and the downstream ERa-
signaling cascade. Of these endocrine therapeutic agents, tamox-
ifen is the most commonly used anti-estrogen [1,3,4,5]. Anthra-
cyclines and taxanes, used alone or in combination, are the most
prevalent cytotoxic agents for the treatment of breast cancer and
Figure 11. FOXO3a induction does not result in proliferative arrest in the drug resistant MDA-MB-231 breast carcinoma cells. A)
MDA-MB-231-FOXO3a(A3):ER cells were cultured on sterile coverslips and treated for 16 h with or without 200 nM 4-OHT as in Fig. 10, before being
fixed in 4% formaldehyde. FOXO3a(A3):ER was visualized with a rabbit polyclonal antibody against ERa followed by the addition of ALEX488 (green)
labeled anti-rabbit antisera. DAPI (blue) were also applied to visualize the nuclei. B) SRB assays were performed on these cytotoxic resistant MDA-MB-
231 cells, indicating that the induction of FOXO3a(A3) has little effects on the cell proliferation rate of the drug resistant breast carcinoma cells.
doi:10.1371/journal.pone.0012293.g011
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plays a vital role in tamoxifen and cytotoxic chemotherapeutic
drug resistance [10,11,12,13]. Enhanced Akt activity has been
reported to promote resistance to tamoxifen and cytotoxic drugs
by promoting cell proliferation and survival [25]. The transcrip-
tion factor FOXO3a is one of the key effectors of the PI3K-Akt
signaling pathway. FOXO3a can be phosphorylated by Akt,
resulting in its inactivation and nuclear exclusion. The Akt-
FOXO3a axis also mediates the cytotoxic response of chemother-
apeutic drugs, including anthracyclines, (eg. doxorubicin also
called Adriamycin) and taxanes (eg. paclitaxel also called Taxol)
and cisplatin [21,22,23,24,26,27,28,29]. Paclitaxel induces the
nuclear translocation and accumulation of FOXO3a to induce
apoptosis in sensitive breast cancer cell lines [22,27]. In colon
carcinoma cells, cisplatin also promotes the nuclear accumulation
of FOXO3a to induce cell death [26]. Similarly, in CML cells, the
cytotoxic effect of doxorubicin is also mediated by the nuclear
accumulation of FOXO3a [23,24]. However, sustained FOXO3a
activation by doxorubicin doxorubicin can also promote drug
resistance and survival of leukaemic cells by activating the
expression of genes important for drug efflux (eg. ABCB1) and
survival (eg. PIK3CA) [23,24,30].
In a study of 113 breast cancer cases, Hu et al [16] have
previously reported that FOXO3a is localized mainly in the
cytoplasm of breast cancer cells and that predominant cytoplasmic
FOXO3a localization is inversely associated with patient survival.
Contrary to these findings, our immunohistochemistry results
showed that nuclear FOXO3a expression in invasive ductal
carcinoma is associated with lymph node metastasis (p=0.052)
and shortened overall survival time (p=0.014). These data also
indicate that consistent nuclear FOXO3a expression in patient
samples is associated with shorter survival time after treatment, as
most if not all of these patients were treated and monitored after
diagnosis. Nevertheless, our findings are in keeping with another
report showing that predominant nuclear-targeted FOXO3a is
significantly correlated with lymph node metastasis in invasive
ductal breast carcinoma [17]. Furthermore, using the same scoring
system as that of Hu et al [16], we found that cases with higher
nuclear to cytoplasmic FOXO3a expression ratio are also
positively associated with P-Akt expression (p=0.039, Chi-square
test). Consistent with our findings, predominant nuclear expression
of FOXO3a have also been shown to correlate with enhanced
PI3K/Akt activity and acquisition of chemoresistance in chronic
myeloid leukaemia (CML) cell lines [23,24].
Figure 12. Overexpressed active FOXO3a has little effect on cell proliferation and drug sensitivity of the drug resistant breast
cancer cell line MCF-7-Dox
R. MCF-7-Dox
R cells were transiently transfected with the constitutively active FOXO3a(A3) or control vector pcDNA3,
A) The transfected cells were analysed by Western blot analysis for FOXO3a and b-actin expression. B) The cells were treated with 0 to 10 mMo f
doxorubicin for 0, 24, 48 and 72 h and SRB assays were performed on these transfected MCF-7-Dox
R cells after 48 h. The results indicated that the
induction of FOXO3a(A3) has little effect on the cell proliferation rate of the drug resistant breast carcinoma cells and in response to doxorubicin
treatment.
doi:10.1371/journal.pone.0012293.g012
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investigated in a panel of endocrine and cytotoxic chemotherapy
resistant and sensitive breast cancer cell lines to establish the
significance of our findings in vivo and to test the hypothesis that
active FOXO3a is associated with resistance to chemotherapy.
Similar to that observed in doxorubicin-resistant CML cell lines
[23,24], our tissue culture models showed enhanced basal
phosphorylated Akt in tamoxifen-resistant cell lines compared
with the parental sensitive cell line MCF-7. Interestingly, high
levels of nuclear FOXO3a were only detected in doxorubicin (eg.
MCF-7Dox
R and MDA-MB-231) but not tamoxifen (eg. LCC2,
LCC9 and BT474) resistant breast cancer cell lines. In terms of
therapeutic options for breast cancers, although the overall
prognosis associated with tamoxifen resistant breast cancers is
usually poor, these breast cancers may still respond to other
endocrine (eg. Fulvestrant and aromatase inhibitors, including
anastrozole, letrozole and exemestane) as well as cytotoxic
chemotherapy treatments. In fact, approximately 30% of ERa
positive breast patients do not respond to tamoxifen treatment,
which is defined as de novo resistance. Moreover, the majority of
tumours that initially respond to tamoxifen treatment will acquire
resistance over time even with maintained ERa expression
[31,32]. Yet, most of these de novo or acquired endocrine resistant
breast cancers are at least initially sensitive to the cytotoxic
chemotherapy. Consistent with this notion, all the tamoxifen-
resistant cell models tested in the present study, including LCC2,
LCC9, BT474, are sensitive to doxorubicin treatment, whereas the
doxorubicin resistant MCF-7Dox
R and MDA-MB-231, are not
Figure 13. Induction of FOXO3a can confer resistance to the MDA-MB-231 cells. MDA-MB-231-FOXO3a(A3):ER cells were cultured with
200 nM 4-OHT and collected at 0, 4, 8, 24 and 48 h. A) Total cytoplasmic and nuclear extracts were prepared at the times indicated, separated on
polyacrylamide gels, and subjected to immunoblotting with FOXO3a, P-FOXO3a(Thr-32), actin and lamin B1 antibodies. B) SRB assays were performed
on the untreated and 4-OHT-treated MDA-MB-231 cells after 48 h of treatment with various concentrations of doxorubicin. The results indicated that
the induction of FOXO3a (A3) can protect the drug resistant breast carcinoma MDA-MB-231 cells from the effects of doxorubicin.
doi:10.1371/journal.pone.0012293.g013
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resistant to the taxane paclitaxel treatment [22,27]. As a result,
these tamoxifen-resistant breast cancer cells may model breast
cancers that have failed endocrine therapy but remain sensitive to
cytotoxic drug-based treatments, while the resistant cells may
represent breast cancers that have progressed and become
resistant to anthracyclins and taxanes. These drug-resistant,
advanced breast cancers are of worse prognosis, as their treatment
options are very limited. The cytotoxic chemotherapeutic resistant
cell lines and the invasive ductal breast carcinoma have numerous
significant overlapping clinical and pathological features. In this
study, we show that they at least share a common molecular
phenotype of sustained nuclear FOXO3a expression. Taken
together our data from the cell culture models help to support
and explain our immunocytochemistry findings that in advanced
breast cancers FOXO3a is predominantly nuclear localized
despite the presence of phophorylated Akt. This also provides in
vitro evidence suggesting sustained nuclear FOXO3a expression
predicts poor survival and chemotherapy resistance.
Our in vitro cell culture experiments confirmed that overexpres-
sion of active FOXO3a(A3) in both MCF-7 and MDA-MB-231
can indeed enhance Akt activity, supporting the feedback
mechanism via the PI3K/Akt pathway. However, overexpression
of the active FOXO3a(A3) can efficiently inhibit cell proliferation
in the chemosensitive breast cancer MCF-7 but has little effect in
the resistant MDA-MB-231 cells. Previously, FOXO3a has also
been shown to induce the expression of the cell cycle inhibitor
p27
Kip1 and the pro-apoptotic Bcl-2 protein Bim to induce
proliferation arrest and apoptosis, respectively, in MCF-7 breast
cancer cells. In line with this, doxorubicin treatment of the
sensitive MCF-7 cells also resulted in re-localization of FOXO3a
to the nucleus in our studies. Thus the enhanced P-Akt expression
resulting from FOXO3a induction in MCF-7 is insufficient to
counteract the action of activated FOXO3a, resulting in an overall
decrease in cell viability. However, in the chemoresistant cell line
MDA-MB-231, the chemoresistant cells may have already
adopted as yet unknown mechanisms to avoid the anti-
proliferative effects of activated FOXO3a, remaining unresponsive
to cell cycle arrest and apoptosis under drug treatment.
The sustained nuclear localization of FOXO3a may also
contribute to the increased PI3K-Akt activity observed in the
chemoresistant breast cancer cells. Treatment of MDA-MB-231-
FOXO3a:ER cells but not the MDA-MB-231 with 4-OHT was
sufficient to induce P-Akt expression, suggesting that the increase
in FOXO3a activity is causative for the induction of PI3K-Akt
activity. Moreover, induction of FOXO3a activity also resulted in
the induction of expression of PIK3CA and IGF-R1, two
components of the PI3K-Akt signaling cascade. The increase in
expression levels of PIK3CA and IGF-R1 as well as other
components of PI3K-Akt signaling pathway by FOXO3a may be
sufficient for the induction Akt phosphorylation and activity if
their expression levels are limiting in these breast cancer cells.
FOXO3a activity is likely to be deregulated in both the invasive
ductal breast carcinoma associated with poor survival, as well as
the anthracyclin-resistant breast cancer cell lines as in both cell-
types nuclear-localized FOXO3a failed to elicit its anti-prolifer-
ative effects. Consistently, induction of FOXO3a activity and
nuclear localization using 4-OHT in the drug-resistant MDA-MB-
231-FOXO3a(A3):ER cells did not have an appreciable effects on
the cell proliferation. Furthermore, expression of an active form of
FOXO3a can enhance the resistance to doxorubicin in the MDA-
MB-231, particular at higher doses. The molecular basis for this is
unclear but can be due to post-translational modifications and/or
differential recruitment of co-factors. Nevertheless, sustained
nuclear localization of FOXO3a may be a crucial molecular
marker for chemotherapy resistance and poor prognosis in breast
cancer. Consistent with the idea that overexpression of FOXO3a
can contribute to tumour progression, a recent study showed that
FOXO3a promotes tumour cell invasion and metastasis through
the induction of matrix metalloproteinases. As such, depletion of
FOXO3a from cancer cells results in decreased tumour size as a
result of attenuated invasive migration [33]. Together these data
suggest that lymph node metastasis and poor survival in invasive
ductal breast carcinoma are linked to an uncoupled of the Akt-
FOXO3a signaling axis, as in these breast cancers active Akt fails
to inactivate and re-localize FOXO3a to the cytoplasm and that
nuclear-targeted FOXO3a does not induce cell death or cell cycle
arrest.
In summary, sustained nuclear FOXO3a expression in breast
cancer may culminate in cancer progression and the development
of an aggressive phenotype similar to that observed in cytotoxic
chemotherapy resistant breast cancer cell models and, can
significantly attenuate their response to tamoxifen and cytotoxic
chemotherapy. Studying the expression profiles of the components
of the Akt-FOXO3a axis, in breast cancer patients might help
predict and monitor their response to chemotherapy. Further
investigations will be required to determine the mechanism by
which FOXO3a nuclear localization and Akt activity are
uncoupled in resistant cancer cells. A better understanding of
the mechanism by which Akt and FOXO3a are regulated, as well
as their roles in cancer progression, drug sensitivity and resistance,
may turn these proteins into crucial therapeutic targets and
prognostic markers for breast cancer and other malignancies.
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